Embed Size (px)
Citation preview
Organized by ReSViNET 4th RESVINET CONFERENCE ON RSV THERAPEUTICS
RSV VACCINES FOR THE WORLD
November 29th – December 1st 2017 Málaga, Spain
ORGANIZING COMMITTEE
Chair – Janet Englund Children's Hospital & Medical Center, Seattle, United States Chair – Asuncion Mejias The Research Institute At Nationwide Children's Hospital, Columbus, Ohio, United States Leyla Kragten-Tabatabaie Julius Clinical, Zeist & University Medical Center Utrecht, Utrecht, The Netherlands Louis Bont Wilhelmina Children’s Hospital University Medical Center Utrecht, Utrecht, The Netherlands Tessa Kliest Julius Clinical, Zeist, The Netherlands Natalie Mazur Wilhelmina Children’s Hospital University Medical Center Utrecht, Utrecht, The Netherlands
SCIENTIFIC ADVISORY COMMITTEE Ruth Karron Johns Hopkins Bloomberg School of Public Health, Baltimore, United States Louis Bont Wilhelmina Children’s Hospital University Medical Center Utrecht, Utrecht, The Netherlands
Helen Chu University Of Washington, Washington, United States
Janet Englund Children's Hospital & Medical Center, Seattle, United States
Ann Falsey University Of Rochester Medical Center, New York, United States
Barney Graham Viral Pathogensis Laboratory And Translational Science Core & National Institute Of Allergy And Infectious Diseases, Bethesda, United States
Deborah Higgins RSV Vaccine Project at Path, Seattle, Washington, United States
Leyla Kragten-Tabatabaie Julius Clinical, Zeist & University Medical Center Utrecht, Utrecht, The Netherlands
Asuncion Mejias The Research Institute At Nationwide Children's Hospital, Columbus, Ohio, United States
Harish Nair Usher Institute Of Population Health Sciences &Informatics & The University Of Edinburgh Medical School, Edinburgh, United Kingdom
Marta Nunes University Of Witwatersrand, Johannesburg, South Africa & Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
Peter Openshaw Faculty Of Medicine, National Heart & Lung Institute, Imperical College London, London, United Kingdom
Pedro A. Piedra Baylor College Of Medicine, Texas, United States
PROGRAM | DAY 1 WEDNESDAY 29 NOVEMBER
11:00 – 15.00 ReSViNET Board Meeting
12:00 Registration and badge retrieval
16:00 – 16:15
16:15 – 16:45
Welcome and opening by Asuncion Mejias & Janet Englund
Keynote Lecture: RSV F structural biology for beginners: antigenic sites and epitopes
(Jason McLellan)
Session I RSV BURDEN AND INFANT MORTALITY
16:45 – 17:00
17:00 – 17:30
17:30 – 18:00
18:00 – 18:30
Session introduction, identifying gaps and aims of session (Chair: Fernando
Polack/Vasee Moorthy)
RSV Burden: Global mortality (Harish Nair)
The burden of RSV community mortality and how to tackle it (Fernando Polack)
General round table discussion
18:30 – 19:30 YOUNG RESEARCHERS TOURNAMENT
(4 selected short presentations by young researchers)
20:00
Welcome Drinks and Tapas
Session II VIRUS STRUCTURE AND VACCINE DESIGN
08:30 – 08:45
08:45 – 09:15
09:15 – 09:45
09:45 – 10:15
10:15 – 10:45
Session introduction, identifying gaps and aims of session (Chair: Barney Graham/Ruth
Karron)
Viral Fusion Proteins: Structure-Guided Vaccine Antigen Design (Barney Graham)
Progress in the Development of Live Attenuated RSV Vaccines (Ruth Karron)
Accelerating vaccine development global program (Deborah Higgins)
Interactive round table discussion with the speakers
10:45 – 11:30 Coffee/Tea break & Posters
Session III RSV ANTIBODIES, ARE THEY THE MAIN SURROGATE OF PROTECTION?
11:30 – 11:45
11:45 – 12:15
12:15 – 12:45
12:45 – 13:15
13:15 – 13:30
Session introduction, identifying gaps and aims of session (Chair: Helen Chu/Pedro
Piedra)
Transplacental antibody transfer, does time matters? (Helen Chu)
Is it pre F, post F or G? (Jose Melero)
What is the threshold of protection? (Pedro Piedra)
Interactive round table discussion with the speakers
13:30 – 14:30 Lunch
Session IV RSV IN VULNERABLE POPULATIONS
14:30 – 14:45
14:45 – 15:05
15:05 – 15:25
15:25 – 15:45
15:45 – 16:00
Session introduction, identifying gaps and aims of session (Chair: Janet
Englund/Octavio Ramilo)
RSV burden in preterm infants (Anne Greenough)
RSV in immunocompromised patients (Jan Englund)
Human volunteer challenge and RSV vaccines for adults: what role could there be?
(Peter Openshaw)
Interactive round table discussion with the speakers
16:00 – 16:45 Coffee/Tea break & Posters
Session V RSV SURVEILLACE AND GUIDELINES
16:45 – 16:50
16:50 – 17:10
17:10 – 17:30
17:30 – 17:50
17:50 – 18:10
18:10 – 18:30
18:30 – 18:45
18:45 – 19:45
Session introduction, identifying gaps and aims of session (Chair: Asuncion Meijas)
WHO Surveillance and efforts on RSV vaccine development (TBA)
Guideline on the clinical evaluation of medicinal products indicated for the prophylaxis
or treatment of RSV disease (Mair Powell, EMA)
Viewpoint FDA on RSV prevention (TBA)
RSV surveillance in the United States (Susan Gerber, CDC)
RSV Vaccines for antimicrobial resistance (Keith Klugman, Bill & Melinda Gates
Foundation)
Interactive round table discussion with the speakers
YOUNG RESEARCHERS EXPERT WORKSHOP (only for young researchers to attend)
20:00 – 23:00 Dinner
PROGRAM | DAY 2 THURSDAY 30 NOVEMBER
PROGRAM | DAY 3 FRIDAY 1 DECEMBER
Session VI STATUS OF VACCINE DEVELOPMENTS
08:30 – 08:35
08:35 – 09:00
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
09:45 – 10:00
10:00 – 10:15
10:15 – 10:30
10:15 – 10:45
Session introduction, identifying gaps and aims of session (Chair: Ann Falsey/Keith
Klugman)
History and future of RSV vaccines (Ed Walsh)
Company 1*
Company 2
Company 3
Company 4
Company 5
Company 6
Interactive round table discussion with the speakers
*All Companies involved in RSV manufactory will be invited to send an abstract which will be reviewed and
evaluated by the organizing committee. Based on the scientific content and value 6 will be selected to speak at the
venue.
10:45 – 11:30 Coffee/Tea break & Posters
Session VII SURROGATE MARKERS OF VACCINE EFFICACY: SEROLOGY AND BEYOND
11:30 – 11:35
11:35 – 12:05
12:05 – 12:35
12:35 – 13:05
13:05 – 13:30
Session introduction, identifying gaps and aims of session (Chair: Peter Openshaw
/Marta Nunes)
Predictors to immune responses to vaccination in young infants (Octavio Ramilo)
Clinical endpoints in trials of RSV vaccines in pregnant women: study design issues,
assessment of safety and effectiveness (Marta Nunes)
Immune response to vaccines in the elderly (Ann Falsey)
Round Table Discussion with the speakers
13:30 – 14:30 Lunch
Session VIII RSV AND LONG-TERM SEQUELAE
14:30 – 14:40
14:40 – 15:10
15:10 – 15:40
15:40 – 16:10
16:10 – 16:30
16:30 – 16:40
16:40 – 17:00
Session introduction, identifying gaps and aims of session (Chair: Louis Bont /Renato
Stein)
The epidemiological link between RSV and asthma (Tina Hartert)
Lessons learned from Immunoprophylaxis RCTs (Eric Simoes)
Follow-up in RSV Vaccine Trials: how long is enough? (Louis Bont)
Interactive round table discussion with the speakers
Announcement Winner Young Researchers Tournament (Natalie Mazur/Leyla Kragten)
Closing Remarks Asuncion Mejias and Louis Bont
LOCATION
The RSV Vaccines for the World 2017 will be held in heart of the Spanish city Málaga, in Cine Albéniz. Cine Albéniz is an old characteristic cinema which is located in the historic centre of Málaga next to the roman theatre which was built in the 1st century AD and the Alcabaza castle which was built in order to protect the city from its enemies. Málaga is a city on the Mediterranean in South Spain and the heart of the Costa del Sol. The vibrant cosmopolitan city of Málaga is situated on the beautiful Andalucía coastline. Blessed with sunshine, Málaga provides lively nightlife, museums and exceptional seafood restaurants alongside wide boulevards, swaying palm trees and beautiful beaches. Guests can enjoy the beautiful and quiet seaside, visit the Picasso museum and Picasso’s birth house, walk through the small and picturesque streets in the historic centre and have the possibility to encounter Antonio Banderas, who is the pride of the city.
PARTICIPANT REGULAR FEE (PAYMENT RECEIVED BY 31 OCT.)
LATE FEE (PAYMENT RECEIVED AFTER 1ST OF NOV.)
BENEFITS LINKED TO THE REGISTRATION FEE
Full Participants € 750 € 880
• Attendance to all scientific sessions • Poster sessions • Invitation to the Opening Reception • Refreshments during the meeting and
lunch • Dinner and networking on 30th of
November • Congress material
(PhD) Students, Fellows and Trainees
€ 295 € 365
• Attendance to all scientific sessions • Poster sessions • Activities young researchers
(presentation tournament & masterclass)
• Invitation to the Opening Reception • Refreshments during the meeting and
lunch • Dinner and networking on 30th of
November • Congress material
REGISTRATION & FEES
TRAVEL AWARDS
ReSViNET is committed to contribute to support, based on quality, developing country participants and young researchers. TRAVEL FELLOWSHIP AWARD POLICY AND REQUIREMENTS Bursaries will be available for young researchers such as PhD students, post-docs, medical
residents or certified specialists (with no more than 3 years practice), judged on the quality of abstracts.
Priority will be given to applicants from an economically disadvantaged area. Click Here to view the list. However, applicants from all countries are welcome to submit.
Applicants must currently work or study in the field of respiratory infectious diseases, and must provide documentation on their institution’s letterhead with a letter from the department head confirming their current position.
One application per registrant.
The master class is exclusively for young researchers such as PhD students, post-docs, medical residents or certified specialists (with no more than 3 years practice), given by an expert in the field of RSV. The focus of the master class will address an overarching theme in medical research. Attendance will be through an application process as there are limited spaces available.
MASTER CLASS
Send all documentation to [email protected] SUBMISSION DEADLINE SEPTEMBER 1, 2017
MORE INFORMATION WILL FOLLOW SOON
ABSTRACT SUBMISSION GUIDELINES
Abstract Submission Starts June, 2017
Abstract Submission Deadline Friday, September 1, 2017
Notification of Selected Abstracts Friday, September 29, 2017
Registration Deadline for Selected Presenters Wednesday, October 25, 2017
ABSTRACT SUBMISSION GUIDELINES Please follow the instructions listed below:
Abstracts can be submitted to [email protected]. The email subject must clearly state:
ABSTRACT SUBMISSION RSV VACCINES FOR THE WORLD MEETING 2017. Abstracts must be received by the announced deadline. Abstracts received after the
deadline will not be considered. Submission of an abstract acknowledges the acceptance for the abstract to be published in
the official meeting publications. Presenting authors must be registered participants in order to be scheduled for poster
sessions and presentation. Abstracts must be submitted in English. Abstracts over 250 words will not be accepted. Please indicate if you wish to participate in the Young Researchers Tournament.
The Scientific Committee will review and determine whether the abstract will be accepted as a poster presentation or participation in the Young Researchers Tournament, with consideration given to the author's preference.
The presenting author is assumed to have approval from all co-authors to submit the abstract.
ABSTRACT PREPARATION Before you begin, please prepare the following information: Contact details presenting author
Email address Full postal address Daytime and evening phone number
Details (co)author(s) Full first and family name(s) (upper and lowercase for example John C. Smith.) Affiliation details (department, institution/hospital, city, state (if relevant), country)
Abstract title - limited to 25 words in UPPER CASE Abstract text - limited to 250 words including acknowledgements
YOUNG RSV RESEARCHERS TOURNAMENT
PARTICIPATION PhD students, post-docs, medical residents or certified specialists (with no more than 3 years practice since completing training or PhD) are eligible to apply. Eligible candidates may indicate that they wish to participate in the tournament when submitting an abstract. Written confirmation from the head of a candidate’s department about resident or PhD status has to be provided and submitted to [email protected]. SELECTION OF CANDIDATES The Organizing Committee will select 4 candidates to participate in the tournament on the basis of the abstract content. FINANCIAL SUPPORT The conference registration fee will be waived for candidates who are selected for the tournament.
PRESENTATION Each candidate is allotted 10 minutes for presentation of his or her research and 5 minutes to answer questions from the jury. The presentations will take place on the first evening of the conference, November 29, 2017. JURY The jury consists of members of the ReSViNET board, RSV vaccines for the world organizing committee, and SAC members. EVALUATION Candidates will be judged on (1) the scientific value of the work presented, (2) the quality of the oral presentation, and (3) the quality of responses to the jury. PRIZE The winner of the tournament will receive a prize consisting of free registration, accommodation as well as a travel grant for the ReSViNET 5th meeting in 2019. The prize is not transferable and will not be paid off in cash.
ACKNOWLEDGEMENTS
Platinum Supporters*
Gold Supporters*
Silver Supporters
*Limited availability
The Organising Committee and the Board of ReSViNET would like to express gratitude and acknowledge the following companies and institutes for their generous support of the RSV Vaccines for the World conference 2017, organised by ReSViNET.
Bronze Supporters
ReSViNET
ReSViNET is an international network of clinician
scientists with an integrated, multidisciplinary and
translational research approach focused on RSV
infection. ReSViNET is stimulating and performing
research aiming to understand the burden of RSV
infection, to advocate for better care for patients
with RSV infection and to provide effective
partnerships with relevant stakeholders.
ReSViNET Annual Meetings are devoted
exclusively to RSV infection prevention and
treatment and is focusing on the scientific
developments and demands in RSV field.
We aim to bring together the scientific data and
expertise, connecting different stakeholders
involved in RSV research e.g. Scientists, policy
makers and Pharmaceutical companies and
stimulating discussions regarding the
opportunities for future international
collaboration and achievement in our field.
WHY JOIN US?
• CONTINUE FOCUSING ON DEVELOPING RSV THERAPIES AND VACCINES •REACH ACADEMIC LEADERS AND
TOP SCIENTISTS IN THE FIELD •NETWORKING WHILE WORKING
• CUTTING-EDGE
SCIENTIFIC RESEARCH •OPPORTUNITIES FOR FUTURE
INTERNATIONAL COLLABORATION
We look forward in welcoming you to Málaga between November 29th to December 1st for the RSV Vaccines for the World conference organised by ReSViNET. If you have any questions or require additional information, please contact: Leyla Kragten-Tabatabaie, PhD ReSViNET Scientific Network Manager t +31 (0)6 11331391 e [email protected] e [email protected] w www.resvinet.org
